These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 31278272)

  • 1. Target preference of Type III-A CRISPR-Cas complexes at the transcription bubble.
    Liu TY; Liu JJ; Aditham AJ; Nogales E; Doudna JA
    Nat Commun; 2019 Jul; 10(1):3001. PubMed ID: 31278272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNA and DNA Targeting by a Reconstituted Thermus thermophilus Type III-A CRISPR-Cas System.
    Liu TY; Iavarone AT; Doudna JA
    PLoS One; 2017; 12(1):e0170552. PubMed ID: 28114398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conditional tolerance of temperate phages via transcription-dependent CRISPR-Cas targeting.
    Goldberg GW; Jiang W; Bikard D; Marraffini LA
    Nature; 2014 Oct; 514(7524):633-7. PubMed ID: 25174707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-specific degradation of transcripts promotes plasmid clearance during type III-A CRISPR-Cas immunity.
    Rostøl JT; Marraffini LA
    Nat Microbiol; 2019 Apr; 4(4):656-662. PubMed ID: 30692669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamics of Cas10 Govern Discrimination between Self and Non-self in Type III CRISPR-Cas Immunity.
    Wang L; Mo CY; Wasserman MR; Rostøl JT; Marraffini LA; Liu S
    Mol Cell; 2019 Jan; 73(2):278-290.e4. PubMed ID: 30503774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type III CRISPR-Cas Immunity: Major Differences Brushed Aside.
    Tamulaitis G; Venclovas Č; Siksnys V
    Trends Microbiol; 2017 Jan; 25(1):49-61. PubMed ID: 27773522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-transcriptional DNA and RNA Cleavage during Type III CRISPR-Cas Immunity.
    Samai P; Pyenson N; Jiang W; Goldberg GW; Hatoum-Aslan A; Marraffini LA
    Cell; 2015 May; 161(5):1164-1174. PubMed ID: 25959775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The CRISPR-associated DNA-cleaving enzyme Cpf1 also processes precursor CRISPR RNA.
    Fonfara I; Richter H; Bratovič M; Le Rhun A; Charpentier E
    Nature; 2016 Apr; 532(7600):517-21. PubMed ID: 27096362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. United we stand: big roles for small RNA gene clusters.
    Felden B; Paillard L
    RNA; 2017 Feb; 23(2):131-133. PubMed ID: 27881475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ribonuclease activity of Csm6 is required for anti-plasmid immunity by Type III-A CRISPR-Cas systems.
    Foster K; Kalter J; Woodside W; Terns RM; Terns MP
    RNA Biol; 2019 Apr; 16(4):449-460. PubMed ID: 29995577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adaptation in bacterial CRISPR-Cas immunity can be driven by defective phages.
    Hynes AP; Villion M; Moineau S
    Nat Commun; 2014 Jul; 5():4399. PubMed ID: 25056268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crystal Structures of Csm2 and Csm3 in the Type III-A CRISPR-Cas Effector Complex.
    Takeshita D; Sato M; Inanaga H; Numata T
    J Mol Biol; 2019 Feb; 431(4):748-763. PubMed ID: 30639408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of single guide RNA transcription for efficient CRISPR/Cas-based genomic engineering.
    Ui-Tei K; Maruyama S; Nakano Y
    Genome; 2017 Jun; 60(6):537-545. PubMed ID: 28177825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Different Target Sequences on Type III CRISPR-Cas Immunity.
    Maniv I; Jiang W; Bikard D; Marraffini LA
    J Bacteriol; 2016 Jan; 198(6):941-50. PubMed ID: 26755632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shooting the messenger: RNA-targetting CRISPR-Cas systems.
    Zhu Y; Klompe SE; Vlot M; van der Oost J; Staals RHJ
    Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29748239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary processing of CRISPR RNA by the endonuclease Cas6 in Staphylococcus epidermidis.
    Wakefield N; Rajan R; Sontheimer EJ
    FEBS Lett; 2015 Oct; 589(20 Pt B):3197-204. PubMed ID: 26364721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic characterization of antiplasmid immunity through a type III-A CRISPR-Cas system.
    Hatoum-Aslan A; Maniv I; Samai P; Marraffini LA
    J Bacteriol; 2014 Jan; 196(2):310-7. PubMed ID: 24187086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Approaches to study CRISPR RNA biogenesis and the key players involved.
    Behler J; Hess WR
    Methods; 2020 Feb; 172():12-26. PubMed ID: 31325492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dealing with the evolutionary downside of CRISPR immunity: bacteria and beneficial plasmids.
    Jiang W; Maniv I; Arain F; Wang Y; Levin BR; Marraffini LA
    PLoS Genet; 2013; 9(9):e1003844. PubMed ID: 24086164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type III-A CRISPR immunity promotes mutagenesis of staphylococci.
    Mo CY; Mathai J; Rostøl JT; Varble A; Banh DV; Marraffini LA
    Nature; 2021 Apr; 592(7855):611-615. PubMed ID: 33828299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.